Clinical presentation is complex and often involves multi-systematic stress. Early identification and standardized clinical treatment are essential for improving prognosis. Diagnosis of this disease requires a combination of clinical presentation, imaging inspection, laboratory testing and pathology.
The platform can assist in bringing together a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the course of the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HLIFRT. The platform serves a team of internationally authoritative experts at home and abroad in the field of blood tumours in China, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.